Impact of a Palliative Care Model on Patient Knowledge and Attitudes
Official title: A Palliative Care Model Impact on Knowledge and Attitudes
Run by Hunter College of City University of New York · NCT06860932 · Data updated 2026-11-12
This study tests if a video about palliative care can help people with Multiple Sclerosis understand their treatment options better than just reading a pamphlet.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Hunter College of City University of New York Academic / other |
| Locations | 2 sites (New York, New York and 1 other locations) |
| Status | Recruiting |
| Started | February 1, 2025 |
| Main results expected | June 1, 2026 |
| Study ends | June 30, 2026 |
| Registry record updated | April 22, 2026 |
| Trial ID | NCT06860932 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18-65 diagnosed with MS, NMOSD, or anti-MOG for at least two years who can communicate in English.
✕Probably not a fit
Patients with significant cognitive impairment or major depressive disorder may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the effects of a palliative care decision aid video on patients with Multiple Sclerosis (MS) compared to a control group receiving written information. Participants will be randomly assigned to either view the video or read an informational sheet, and their goals-of-care preferences will be assessed at baseline, immediately after the intervention, and three months later. The study aims to measure changes in treatment preferences, knowledge, and decision-making preparation. It utilizes a structured approach to ensure balanced representation across demographics.
Why it matters
Potential benefit: If successful, this study could enhance patient understanding and decision-making regarding palliative care options for those with chronic progressive illnesses.
How similar studies have gone: Other studies have shown positive outcomes using similar palliative care decision aids, indicating potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosed with MS, NMOSD, or anti-MOG, at least 2 years after their diagnosis. * Aged 18-65 * Speak English since all instruments are available in English. Exclusion Criteria: * Visually impaired (note, hearing impaired is not an exclusion criterion as the video is closed captioned). * Psychological state not appropriate for PC discussions as determined by the Patient Health Questionnaire 9 (PHQ9). * A score of 11 or higher, indicative of major depressive disorder, will be referred to immediate management and excluded from the study. * Unable to participate in PC discussions due to cognitive impairment as determined by the Processing Speed Test (PST) score below -1.5 Z score.
Where it's running
-
Judith Jaffe Multiple Sclerosis Center
New York, New York, United States Recruiting -
Hunter College
New York, New York, United States Recruiting
Study contacts
- Study coordinator: Aliza Ben-Zacharia, PhD
- Email: ab1288@hunter.cuny.edu
- Phone: 6462262616
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
QH103 (universal CD19 CAR-γδT) cell injections for relapsed or treatment‑resistant antibody-driven neurological autoimmune diseases
This Phase 1 test will see if QH103 (universal CD19 CAR-γδT) cell injections are safe and tolerated in adults with relapsed or treatment‑resistant antibody-mediated neurological diseases such as MS, NMOSD, AE, CIDP, or MG.
-
Can QSM MRI help tell MS from age-related brain changes in older adults
This study tests whether an advanced MRI technique called QSM can better differentiate MS-related brain lesions from age-related or small vessel changes in people aged 50–70.
-
Escalation versus induction therapy for relapsing MS starting after age 50
This project will test whether starting with stronger, highly effective treatments or beginning with moderate drugs and escalating later changes the risk of inflammatory relapses for people whose relapsing MS began after age 50.
-
Observational study on CNS inflammatory demyelinating diseases in the Chinese population
This study is looking to understand how certain brain diseases, like Multiple Sclerosis, affect people in China and what factors might influence their progression and treatment.
-
C-CAR168 treatment for autoimmune diseases not responding to standard therapy
This study is testing a new treatment called C-CAR168 to see if it can help adults with autoimmune diseases that haven't improved with standard therapies.
-
Exploring brain imaging to understand neurodegeneration in multiple sclerosis
This study is testing how brain imaging can help us understand the brain changes in people with multiple sclerosis who have been living with the condition for a long time.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.